Investment10 Jul 2025, 05:01 pm
Glenmark Pharmaceuticals, Ichnos Glenmark Innovation Announce Global Commercialization Strategy for ISB 2001 in Oncology and Autoimmune Diseases
AI Summary
Ichnos Glenmark Innovation (IGI) and Glenmark Pharmaceuticals announced a global commercialization strategy for ISB 2001, a lead investigational asset developed by IGI for oncology and autoimmune diseases. The strategy follows an exclusive licensing agreement with AbbVie, under which IGI partners with AbbVie for global development, manufacturing, and commercialization in North America, Europe, Japan, and Greater China. Glenmark Pharmaceuticals will develop, manufacture, and lead commercialization of ISB 2001 across Emerging Markets. ISB 2001 is a trispecific T-cell engager targeting BCMA and CD38 on myeloma cells and CD3 on T cells, currently in Phase 1 clinical development for relapsed/refractory multiple myeloma.
Key Highlights
- IGI and Glenmark Pharmaceuticals announce global commercialization strategy for ISB 2001 in oncology and autoimmune diseases.
- Licensing agreement with AbbVie for global development, manufacturing, and commercialization in select regions.
- Glenmark Pharmaceuticals to develop, manufacture, and lead commercialization across Emerging Markets.
- ISB 2001 is a trispecific T-cell engager in Phase 1 clinical development for relapsed/refractory multiple myeloma.
- Data presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting demonstrated a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30%.